Business Wire

Innovid Bolsters Omni-channel Advertising Offering With Acquisition of Herolens

Share

Innovid, the only independent omni-channel advertising and analytics platform built for television, today announced the acquisition of Herolens, an international advertising software company with expertise in display creative optimization technology. The acquisition expands Innovid’s existing global ad serving, dynamic creative personalization, and advanced measurement capabilities to include display formats alongside the company’s award-winning TV, video, and social solutions.

Herolens is the leading creative management platform headquartered in Latin America, focused on delivering data-driven, dynamic and personalized creative on behalf of brands such as Coke, Renault, and Mercado Libre. Known for their flexible self-service, hybrid and full-service models, clients use Herolens as a central hub for digital asset management and dynamic creative customization, as well as display ad serving.

“We’ve heard first-hand from our clients, the world’s largest TV spenders, the need to leverage data to connect all channels, including TV,” said Zvika Netter, CEO and Co-Founder, Innovid. “We continue to lead with the most advanced TV and video capabilities in the market, while also providing brands their desired goal of a single stack via adding support for display ads. With TV at the center, brands can now go deep and wide seamlessly managing connected experiences across TV video, social, mobile and display to improve customer engagement and business outcomes.”

Netter continued, “As brands look to own their data for a single view of the consumer and seek a global independent alternative to the single stack solutions provided by the duopoly of Google and Amazon, Innovid is the only leading alternative for large TV advertisers because of the depth of our offering in TV and the breadth of our offering that is now omni-channel.”

“We were impressed that the largest global brands have chosen Innovid for their video expertise, their first-to-market interactive and data-driven television formats, accredited measurement in OTT and dynamic capabilities across social platforms.” said Alan Karpovsky, Co-CEO, Herolens and selected by Forbes 30 under 30. “Joining the Innovid team will allow us to bring our display expertise to their global customers.”

A profitable company, Herolens built a strong product and engineering team which constitutes almost all of their 40 employees. They, along with the Herolens leadership team including co-founders Alan Karpovsky, Cristian Pereyra, and José Galindo will join the Innovid team. Innovid will continue to operate their office in Buenos Aires which will function as Innovid’s LATAM HQ with representatives in both Mexico and Columbia.

“We’re eager to be a core component of this omni-channel solution, and excited to join this award winning company,” said José Galindo, Co-Founder, Herolens. “From their leading innovation in connected TV to their consistent recognition as a best place to work, Innovid has a culture and commitment to excellence that resonated with us.”

About Innovid

Innovid is the only independent omni-channel advertising and analytics platform built for television. We use data to enable the personalization, delivery, and measurement of ads across the widest breadth of digitally enabled channels in the market including TV, video, display, social, and OOH. Innovid serves a global client base of brands, agencies, and publishers through over twelve offices across the Americas, Europe, and Asia Pacific.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact: (FOR MEDIA ONLY)
Meghan Heide
Email: pr@innovid.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye